Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

#ESMO21 Expert Video Report on immunotherapy in gastro-oesophageal cancer

Reporting from the ESMO Congress 2021, Elizabeth Smyth comments on the updated results from the CheckMate 649 in advanced gastric, GEJ and oesophageal cancer that confirm chemotherapy + nivolumab as a new standard of care, while the new results of the immunotherapy combination arm show a possible benefit for subgroups of patients only. She further discusses the encouraging results from second line treatment with trastuzumab deruxtecan in patients with HER2-positive gastric cancer. Finally, she explains the encouraging results of the CLDN 18.2-targeted CAR-T cell therapy in digestive cancers.

Abstracts:
LBA7 - First Report of Nivolumab (NIVO) Plus Ipilimumab (IPI) vs Chemotherapy (chemo) and Long-Term Follow-Up of NIVO Plus Chemo vs Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC)/Esophageal Adenocarcinoma (EAC): CheckMate 649 Study - Dr Yelena Janjigian, US
LBA55 - Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen - Prof. Eric Van Cutsem, BE
1372O - CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system - Dr. Changsong Qi, CN

This video is part of a sponsored track. The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings